What question did this study set out to answer?

To investigate the incidence, clinical features, and risk factors of cardiac complications associated with conditioning regimens in patients receiving bone marrow transplantation.

May 15, 1986Cancer

Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations

View Full Paper

Ask AI

Bookmark

Why the study?

What is the incidence and nature of cardiac complications following bone marrow transplantation with cyclophosphamide-based pregraft regimens?

Population

63 patients undergoing bone marrow transplantation between February 1977 and October 1983.

Design

Case_series

Authors

BCBruno CazinHôpital Claude Huriez NGNorbert Claude GorinSorbonne Université JLJ.P. LaporteSciensano (Belgium)

Discussion

Member takes

Implication

Warrants cardiac monitoring after cyclophosphamide-based BMT; leaves open safer regimen selection for prospective study.

Key Points

To investigate the incidence, clinical features, and risk factors of cardiac complications associated with conditioning regimens in patients receiving bone marrow transplantation.
Evaluation of 63 consecutive bone marrow transplant recipients (57 autologous, 6 allogeneic) treated between February 1977 and October 1983 in France, combining retrospective (n=49) and prospective (n=14) analyses.
Conditioning regimens consisted of TACC chemotherapy (n=39), cyclophosphamide combined with total body irradiation (n=16), or multiple chemotherapeutic agents (n=8).
Overall cardiac morbidity occurred in 43% of patients and mortality reached 9%, with 6 fatal cases of cardiomyopathy and/or pericarditis.
Nonfatal cardiac complications included 14 cases of heart failure, 7 cases of isolated pericarditis, and 32 arrhythmias (including 14 bradycardias) distributed across 27 patients.
Cyclophosphamide-containing regimens were the primary drivers of toxicity; key early predictors included sustained weight gain (>2 kg for >48 hours) and an electrocardiogram QRS voltage decrease exceeding 14% by day 4.

Structured PICO

What is the incidence and nature of cardiac complications following bone marrow transplantation with cyclophosphamide-based pregraft regimens?

Population

63 patients undergoing bone marrow transplantation (57 autologous, 6 allogeneic) between February 1977 and October 1983.

Intervention

Bone marrow transplantation with pregraft regimens including cyclophosphamide, 6-thioguanine, cytosine arabinoside, and CCNU (TACC) (n=39), cyclophosphamide associated with whole-body irradiation (n=16), or multiple chemotherapeutic agents (n=8).

Outcome

Cardiac complications (morbidity and mortality)safety

Bone marrow transplantation with high-dose cyclophosphamide-based regimens is associated with significant cardiac toxicity, including fatal cardiomyopathy and heart failure, highlighting the need for early transplantation and preference for whole-body irradiation over high-dose chemotherapy combinations.

Cite This Study

Cazin et al. (1986) studied this question.

synapsesocial.com/papers/6a7871be6789de8d0af7c9b4 https://doi.org/10.1002/1097-0142(19860515)57:10<2061::aid-cncr2820571031>3.0.co;2-h

Topics

Pericardial disease Echocardiography Cardio-oncology

View Full Paper

Ask AI

Bookmark

Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider